Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
What is your approach to treatment when there is a multiple sclerosis reactivation while on natalizumab?
Related Questions
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
What biomarkers best predict the response to B-cell depleting therapies in MS?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
How do you decide when to discontinue immunotherapy for primary angiitis of the central nervous system (PACNS)?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
Which patients will have earlier diagnosis of multiple sclerosis via the new 2024 McDonald Criteria?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
When would you use ofatumumab for anti-NMDAR autoimmune encephalitis?
